Eli Lilly and Company (NYSE:LLY) Shares Sold by WBH Advisory Inc.

WBH Advisory Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% in the second quarter, HoldingsChannel reports. The firm owned 11,493 shares of the company’s stock after selling 303 shares during the quarter. WBH Advisory Inc.’s holdings in Eli Lilly and Company were worth $5,390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Fairfield Bush & CO. bought a new position in shares of Eli Lilly and Company during the first quarter worth about $107,000. Roundview Capital LLC boosted its stake in Eli Lilly and Company by 2.6% during the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after purchasing an additional 53 shares during the period. Merit Financial Group LLC bought a new position in Eli Lilly and Company in the 1st quarter worth about $210,000. NewEdge Advisors LLC increased its stake in shares of Eli Lilly and Company by 9.9% in the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after purchasing an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $561,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on LLY. Cantor Fitzgerald restated an “overweight” rating and issued a $630.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 5th. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $375.00 to $500.00 in a research note on Tuesday, June 20th. UBS Group upped their price objective on shares of Eli Lilly and Company from $447.00 to $498.00 and gave the stock a “buy” rating in a report on Wednesday, May 24th. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $617.00 to $640.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 5th. Finally, Argus upped their price target on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $532.78.

Eli Lilly and Company Trading Up 0.5 %

Shares of NYSE:LLY traded up $2.69 during mid-day trading on Tuesday, hitting $573.97. The stock had a trading volume of 730,063 shares, compared to its average volume of 3,024,253. The company’s 50 day moving average is $512.56 and its 200-day moving average is $439.28. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $601.84. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13. The company has a market cap of $544.86 billion, a PE ratio of 80.02, a P/E/G ratio of 2.37 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. During the same quarter in the prior year, the company earned $1.25 earnings per share. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 9.84 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 62.87%.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 107,022 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the completion of the sale, the insider now directly owns 101,248,810 shares in the company, valued at $46,501,553,456.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 107,022 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the transaction, the insider now directly owns 101,248,810 shares in the company, valued at approximately $46,501,553,456.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total value of $678,445.04. Following the sale, the executive vice president now owns 7,760 shares of the company’s stock, valued at $4,586,004.80. The disclosure for this sale can be found here. Insiders have sold 976,153 shares of company stock worth $21,080,192,113 in the last 90 days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.